WinstonWınston
IR-Med logo

IR-Med

IRME
Medical - Devices · Healthcare
Price
$0.00
+0.00 (+0.00%)
Market Cap
$84,963
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+134.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 30.0M (2020) → 70.5M (2024)

IR-Med Inc. is a small medical device company focused on developing non-invasive diagnostic tools for healthcare providers. Its core product is a device designed to detect ear infections by using infrared light technology to analyze the eardrum, targeting pediatricians and primary care physicians as its main customers. The company operates in the medical diagnostics space, where accurate and quick detection of ear infections — one of the most common reasons children visit doctors — is a persistent clinical need.

IR-Med generates revenue through device sales and potentially related disposables, though it remains in an early commercial stage with very limited revenue to date. The company operates primarily in the United States and is extremely small, with a market cap near zero, reflecting its pre-revenue or near-pre-revenue status. The deeply negative operating margin signals that expenses far exceed sales today, and the key risk is whether the company can secure regulatory clearances, build a sales channel, and scale revenue before exhausting its capital resources.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-82.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$710,000/ year

Declining (-66% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

61.8%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~3 months

$63,000 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

IR-Med has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
N/A
Data not available
Operating Margin
N/A
Data not available
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-23.5%
Shrinking sales (-23.5% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-3219.2%
Burning cash (-3219.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial